British man with Ebola in DR Congo arrives in UK for treatment

A British healthcare worker who contracted Ebola while in the Democratic Republic of Congo (DR Congo) has been transported back to the United Kingdom for treatment. The individual, who has not been named, arrived at RAF Northolt and was then taken to the Royal Free Hospital in north London, where a specialized infectious diseases unit is located. This marks the first confirmed case of a UK national testing positive for Ebola during the current outbreak in DR Congo, which has resulted in over 5,000 fatalities to date.

The Royal Free Hospital has experience in managing Ebola cases, having successfully treated three healthcare professionals evacuated during the West African Ebola crisis in 2014 and 2015. Historically, the UK has seen only four confirmed Ebola cases: one in 1976 linked to a laboratory incident, and three involving health workers combating the West African outbreak, with none of these cases being fatal. A UK government spokesperson emphasized that stringent protocols are in place to manage such cases, assuring the public that the risk remains low.

The DR Congo outbreak, which began in May, has now recorded more than 10,000 confirmed Ebola cases. This ongoing epidemic is the second deadliest Ebola outbreak on record, surpassed only by the one in West Africa during the previous decade. As of the end of last month, the reported fatality rate stands at approximately 48.6%. Ebola infection presents initially with symptoms like vomiting and diarrhoea and can worsen to cause organ failure and internal bleeding. Transmission occurs through contact with the bodily fluids of infected individuals.

This outbreak involves the Bundibugyo strain of the Ebola virus. While no approved vaccine for this variant currently exists, the World Health Organization (WHO) has endorsed the inclusion of two new candidate vaccines into ongoing clinical trials, pending approval from Congolese health authorities. One vaccine is produced by the University of Oxford in partnership with the Serum Institute of India, and the other is developed by Moderna. These trials will mark the first testing of vaccines specifically targeting the Bundibugyo virus during an active outbreak. Additionally, cases have also been confirmed in neighboring countries such as Kenya, Nigeria, and Uganda